These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 26254276)

  • 61. Renal safety outcomes of spironolactone in patients with resistant hypertension.
    Galceran I; Vázquez S; Durán X; Outón S; Pascual J; Oliveras A
    Nefrologia (Engl Ed); 2020; 40(4):414-420. PubMed ID: 31898989
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT)--study protocol.
    Vaclavik J; Sedlak R; Plachy M; Navratil K; Plasek J; Husar R; Kocianova E; Taborsky M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Jun; 155(2):143-8. PubMed ID: 21804623
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Meta-analysis: the efficacy and safety of combined treatment with ARB and ACEI on diabetic nephropathy.
    Ren F; Tang L; Cai Y; Yuan X; Huang W; Luo L; Zhou J; Zheng Y
    Ren Fail; 2015 May; 37(4):548-61. PubMed ID: 25707526
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study.
    Wada T; Inagaki M; Yoshinari T; Terata R; Totsuka N; Gotou M; Hashimoto G
    Clin Exp Nephrol; 2021 Feb; 25(2):120-130. PubMed ID: 32974732
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effect of spironolactone in resistant arterial hypertension: a randomized, double-blind, placebo-controlled trial (ASPIRANT-EXT).
    Václavík J; Sedlák R; Jarkovský J; Kociánová E; Táborský M
    Medicine (Baltimore); 2014 Dec; 93(27):e162. PubMed ID: 25501057
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The effects of spironolactone on nephron function in patients with diabetic nephropathy.
    Ustundag A; Tugrul A; Ustundag S; Sut N; Demirkan B
    Ren Fail; 2008; 30(10):982-91. PubMed ID: 19016150
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension.
    Lindhardt M; Persson F; Oxlund C; Jacobsen IA; Zürbig P; Mischak H; Rossing P; Heerspink HJL
    Nephrol Dial Transplant; 2018 Feb; 33(2):296-303. PubMed ID: 28064163
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
    Rossignol P; Dobre D; McMurray JJ; Swedberg K; Krum H; van Veldhuisen DJ; Shi H; Messig M; Vincent J; Girerd N; Bakris G; Pitt B; Zannad F
    Circ Heart Fail; 2014 Jan; 7(1):51-8. PubMed ID: 24297687
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease.
    Bianchi S; Bigazzi R; Campese VM
    Kidney Int; 2006 Dec; 70(12):2116-23. PubMed ID: 17035949
    [TBL] [Abstract][Full Text] [Related]  

  • 70. BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial.
    Leehey DJ; Zhang JH; Emanuele NV; Whaley-Connell A; Palevsky PM; Reilly RF; Guarino P; Fried LF;
    Clin J Am Soc Nephrol; 2015 Dec; 10(12):2159-69. PubMed ID: 26482258
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparative effectiveness of fourth-line anti-hypertensive agents in resistant hypertension: A systematic review and meta-analysis.
    Sinnott SJ; Tomlinson LA; Root AA; Mathur R; Mansfield KE; Smeeth L; Douglas IJ
    Eur J Prev Cardiol; 2017 Feb; 24(3):228-238. PubMed ID: 27856806
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Life-threatening hyperkalemia: a complication of spironolactone for heart failure in a patient with renal insufficiency.
    Hu Y; Carpenter JP; Cheung AT
    Anesth Analg; 2002 Jul; 95(1):39-41, table of contents. PubMed ID: 12088939
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice.
    Bhuiyan AS; Rafiq K; Kobara H; Masaki T; Nakano D; Nishiyama A
    Hypertens Res; 2019 Jun; 42(6):892-902. PubMed ID: 30664703
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effective antihypertensive strategies for high-risk patients with diabetic nephropathy.
    Van Buren PN; Adams-Huet B; Toto RD
    J Investig Med; 2010 Dec; 58(8):950-6. PubMed ID: 21030879
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
    Lancet; 1997 Jun; 349(9069):1857-63. PubMed ID: 9217756
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Retrospective cohort study to characterise the blood pressure response to spironolactone in patients with apparent therapy-resistant hypertension using electronic medical record data.
    Shuey M; Perkins B; Nian H; Yu C; Luther JM; Brown N
    BMJ Open; 2020 May; 10(5):e033100. PubMed ID: 32461291
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Diabetic nephropathy and arterial hypertension. The effect of antihypertensive treatment.
    Parving HH; Andersen AR; Smidt UM; Christiansen JS; Oxenbøll B; Svendsen PA
    Diabetes; 1983 May; 32 Suppl 2():83-7. PubMed ID: 6400672
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effectiveness of aldosterone blockade in patients with diabetic nephropathy.
    Sato A; Hayashi K; Naruse M; Saruta T
    Hypertension; 2003 Jan; 41(1):64-8. PubMed ID: 12511531
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
    Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
    Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial.
    Oxlund CS; Henriksen JE; Tarnow L; Schousboe K; Gram J; Jacobsen IA
    J Hypertens; 2013 Oct; 31(10):2094-102. PubMed ID: 24107738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.